Relmada Therapeutics
Update in progressRLMD (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Relmada Therapeutics is a US clinical-stage biotech company focused on novel oncology and CNS therapies. Its pipeline includes NDV‑01, a controlled‑release intravesical gemcitabine/docetaxel in Phase 2 for aggressive non‑muscle invasive bladder cancer, and Sepranolone, a neurosteroid epimer of allopregnanolone with Phase 2b‑ready potential for Prader‑Willi syndrome, Tourette syndrome, tremor, and other GABA‑related disorders. It collaborates with Asarina Pharma AB and Trigone. Founded 2004, based in Coral Gables, Florida.
Company score
- Sentiment
- -0.09
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- -0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!